Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

Thwarted in her ambition to become a brewmaster, Kiran Mazumdar-Shaw channeled her frustrations into building a knockoff drug ...

Successful trial results in the next few years could save thousands of lives and generate billions in new annual revenue for ...

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers rega ...

His innovation reduces the cost per gram from $75.00 to just $12.00, and the production time per batch from 9 days to just 5.

AERIFY-1 trial met the primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a clinically me ...

Finally, thanks to labor shortages created by World War II, real opportunities started ... helping to increase the cure rate of ALL in children from 10 percent in the 1950s to more than 80 percent ...

About itepekimab Itepekimab is a fully human monoclonal antibody that binds to and inhibits interleukin-33 (IL33), an initiator and amplifier of broad inflammation in COPD. IL33 is thought to be ...

Drugs for metabolic diseases ... offers less frequent dosing than its two predecessors in the class, Sanofi/Regeneron's Dupixent (dupilumab) and LEO Pharma's Adbry/Adtralza (tralokinumab).

The data forecasts the top 10 best-selling drugs in 2025 by annual revenue ... drug Humira (adalimumab), which is currently the world’s top-selling drug,” says Keshalini Sabaratnam, pharma ...

Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, ...